ES2063851T3 - Compuestos con accion selectiva sobre receptores de adenosina. - Google Patents

Compuestos con accion selectiva sobre receptores de adenosina.

Info

Publication number
ES2063851T3
ES2063851T3 ES90105919T ES90105919T ES2063851T3 ES 2063851 T3 ES2063851 T3 ES 2063851T3 ES 90105919 T ES90105919 T ES 90105919T ES 90105919 T ES90105919 T ES 90105919T ES 2063851 T3 ES2063851 T3 ES 2063851T3
Authority
ES
Spain
Prior art keywords
adenosine
activity
compounds
adenosine receptors
selective action
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90105919T
Other languages
English (en)
Inventor
Norton P Peet
Nelsen L Lentz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Merrell Dow Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharmaceuticals Inc filed Critical Merrell Dow Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2063851T3 publication Critical patent/ES2063851T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)

Abstract

ES DESCUBIERTA ADENOSINA QUE ACTUA SELECTIVAMENTE EN RECEPTORES DE ADENOSINA Y QUE ACTUA EN GENERAL COMO ANTAGONISTAS DE ADENOSINA. DE ESTUDIOS IN VITRO ES CONOCIDO QUE LOS EFECTOS FISIOLOGICOS ESPECIFICOS PUEDEN SER DISTINGUIDOS COMO RESULTADO DE ESTA SELECTIVIDAD Y QUE LA ACTIVIDAD DEL RECEPTOR DE ADENOSINA IN VITRO SE CORRELACIONA CON LA ACTIVIDAD DEL RECEPTOR DE ADENOSINA IN VIVO. LAS PREPARACIONES FARMACEUTICAS DE LOS COMPONENTES SOMETIDOS PUEDEN SER PREPARADOS EN LAS BASES DE LA ACTIVIDAD ENLAZANTE SELECTIVA DE LOS COMPONENTES DESCUBIERTOS AQUI, QUE PUEDEN SER ESPERADOS PARA INCREMENTAR CIERTOS EFECTOS FISIOLOGICOS MIENTRAS SE MINIMIZAN OTROS, TALES COMO DISMINUIR LA PRESION SANGUINEA SIN DISMINUIR EL RITMO DEL CORAZON.
ES90105919T 1989-03-29 1990-03-28 Compuestos con accion selectiva sobre receptores de adenosina. Expired - Lifetime ES2063851T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33040089A 1989-03-29 1989-03-29

Publications (1)

Publication Number Publication Date
ES2063851T3 true ES2063851T3 (es) 1995-01-16

Family

ID=23289598

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90105919T Expired - Lifetime ES2063851T3 (es) 1989-03-29 1990-03-28 Compuestos con accion selectiva sobre receptores de adenosina.

Country Status (18)

Country Link
EP (1) EP0390111B1 (es)
JP (1) JP3014000B2 (es)
KR (1) KR0150635B1 (es)
CN (1) CN1029972C (es)
AR (1) AR245720A1 (es)
AT (1) ATE111466T1 (es)
AU (1) AU623755B2 (es)
CA (1) CA2013381C (es)
DE (1) DE69012388T2 (es)
ES (1) ES2063851T3 (es)
FI (1) FI95133C (es)
HU (1) HU203349B (es)
IE (1) IE63545B1 (es)
IL (1) IL93893A (es)
NO (1) NO173997C (es)
NZ (1) NZ233077A (es)
PT (1) PT93589B (es)
ZA (1) ZA902282B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2152207T3 (es) * 1989-10-20 2001-02-01 Kyowa Hakko Kogyo Kk Derivados condensados de la purina.
ZA914727B (en) * 1990-06-21 1992-03-25 Schering Corp Polycyclic guanine derivatives
DE19629378A1 (de) * 1996-07-20 1998-01-29 Boehringer Ingelheim Kg Neue Triazolopurine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AU2223501A (en) * 1999-12-24 2001-07-09 Kyowa Hakko Kogyo Co. Ltd. Fused purine derivatives

Also Published As

Publication number Publication date
IL93893A (en) 1994-07-31
ZA902282B (en) 1990-12-28
CN1029972C (zh) 1995-10-11
NO173997B (no) 1993-11-22
KR900014390A (ko) 1990-10-23
AR245720A1 (es) 1994-02-28
AU623755B2 (en) 1992-05-21
JP3014000B2 (ja) 2000-02-28
DE69012388D1 (de) 1994-10-20
CN1045974A (zh) 1990-10-10
EP0390111B1 (en) 1994-09-14
ATE111466T1 (de) 1994-09-15
NO901424D0 (no) 1990-03-28
JPH02289574A (ja) 1990-11-29
EP0390111A2 (en) 1990-10-03
AU5218290A (en) 1990-10-04
IL93893A0 (en) 1990-12-23
NO173997C (no) 1994-03-02
CA2013381C (en) 2000-06-20
CA2013381A1 (en) 1990-09-29
HU203349B (en) 1991-07-29
FI95133B (fi) 1995-09-15
NZ233077A (en) 1992-12-23
IE63545B1 (en) 1995-05-17
HUT54160A (en) 1991-01-28
NO901424L (no) 1990-10-01
FI901550A0 (fi) 1990-03-28
PT93589B (pt) 1996-06-28
FI95133C (fi) 1995-12-27
PT93589A (pt) 1990-11-20
DE69012388T2 (de) 1995-04-27
KR0150635B1 (ko) 1998-10-15
IE901142L (en) 1990-09-29
HU901857D0 (en) 1990-08-28
EP0390111A3 (en) 1991-05-08

Similar Documents

Publication Publication Date Title
ES2185615T3 (es) Uso y liberacion controlada de las microcapsulas para estimular el crecimiento de la fibra nerviosa.
GT200000173A (es) Derivados de purina.
GT200000172A (es) Derivados de la purina.
ES2085983T3 (es) Antagonistas de anticuerpos de la interleuquina-4 humana.
ES2087061T3 (es) Utilizacion de ribosido o ribotido de aica para la fabricacion de un medicamento contra la crisis cardiaca o el infarto de miocardio en los pacientes que sufren de ateroesclerosis.
AR024441A1 (es) Agonistas del receptor a2a n-pirazol, composiciones farmaceuticas y el uso de los mismos para preparar un medicamento.
ES2138977T3 (es) Agonistas muscarinicos.
UY26974A1 (es) Agonistas del receptor beta3 adrenérgico y usos de los mismos
ES2196063T3 (es) Utilizacion de agentes antagonistas competitivos de progesterona para la preparacion de medicamentos destinados al tratamiento de hemorragias uterinas disfuncionales.
ES2167592T3 (es) Preparaciones medicamentosas que contienen un enantiomero de bromuro de ipratropio con duracion de la accion prolongada.
ES2171768T3 (es) Inhibidores de la resorcion osea y antagonistas de receptores de vitronectina.
ES2147759T3 (es) Heterociclos no aromaticos sustituidos con aminometileno y uso como antagonistas de la sustancia p.
ES2173873T3 (es) Utilizacion de anticuerpos anti-vegf para el tratammiento del cancer.
ES2151652T3 (es) Derivados de indol como antagonistas del receptor 5ht.
ES2072323T3 (es) Compuestos de piperidina y su preparacion y empleo.
MX9305294A (es) Compuestos de decahidroisoquinolina, procedimiento para su preparacion y formulacion farmaceutica que los comprende.
ES2179945T3 (es) Compuestos de tetralina con actividad de resistencia a multiples farmacos.
ES2086313T3 (es) Nuevos derivados de xantina con efecto antagonista de adenosina.
ES2132105T3 (es) 2-aminometil-cromanos como principios activos en farmacos para el tratamiento de enfermedades del sistema nervioso central.
CO5011096A1 (es) Medicamentos que contienen antagonistas del receptor 5-ht3 para el tratamiento de la ibs
ES2054872T3 (es) Nuevos derivados de acido bencimidazolin-2-oxo-1-carboxilico utiles como antagonistas de los receptores 5-ht.
ES2153820T3 (es) Derivados de benzimidazol, procedimiento para su preparacion y aplicaciones.
AR024440A1 (es) AGONISTAS DEL RECEPTOR A2A DE ETER PROPARGIL FENILICO, COMPOSICIoN FARMACEUTICA Y EL USO DE LOS MISMOS PARA PREPARAR UN MEDICAMENTO.
ES2061019T3 (es) Vendaje elastico tejido o de punto.
ES2058426T3 (es) Empleo de antagonistas de serotonina en el tratamiento de apoplejia cerebral.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 390111

Country of ref document: ES